SCHEMBL1378956

SCHEMBL1378956

COc1ccc(S(=O)(=O)n2cc(-c3cncc(C(N)=O)c3)cc2-c2cc(OC)c(OC)c(OC)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
MAP4K4 O95819 1/20 0.46
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
MAP3K11 Q16584 1/20 0.40
FYN P06241 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TUBB4A P04350 2/20 0.38
TUBB P07437 2/20 0.38
TUBA3C P0DPH7 2/20 0.38
TUBA1B P68363 2/20 0.38
TUBA4A P68366 2/20 0.38
TUBB4B P68371 2/20 0.38
TUBB3 Q13509 2/20 0.38
TUBB2A Q13885 2/20 0.38
TUBB8 Q3ZCM7 2/20 0.38
TUBA3E Q6PEY2 2/20 0.38
TUBA1A Q71U36 2/20 0.38
TUBA1C Q9BQE3 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376476 0.93 MAP3K11 (0.42) CYP11B1CYP11B2MKNK1MKNK2MAP3K11
SCHEMBL1375760 0.82 CYP11B2 (0.48) CYP11B1CYP11B2TUBB4ATUBBTUBA3C
SCHEMBL1379606 0.80 MAP3K11 (0.48) MAP3K11FYNL3MBTL1TUBB4ATUBB
SCHEMBL1375792 0.79 FYN (0.46) MAP3K11FYNLMNAMAPTALPL
SCHEMBL5696246 0.78 L3MBTL1 (0.47) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1379796 0.77 MAPK1 (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1379771 0.77 MAPT (0.37) FYNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1379148 0.74 KDM4E (0.37) FYNL3MBTL1TUBB4ATUBBTUBA3C
SCHEMBL3371555 0.74 CA12 (0.43) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1376787 0.73 CD274 (0.44) ALDH1A1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4716996-B2 2011-07-06 JP claimed
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP claimed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US claimed
EP-1628957-A1 SULFOPYRROLES Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP claimed
WO-2004103968-A1 SULFOPYRROLES APONETICS AG (CH) 2004-12-02 WO claimed
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP disclosed
US-7612064-B2 Sulfopyrroles TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-03 US disclosed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060570-A1 Sulfopyrroles TYK2, ARSA, SULT2A1 CYP11B1 445/4885CYP11B2 369/4885MAP4K4 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.